• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

顺铂联合卡培他滨诱导化疗治疗局部鼻咽癌可提高生活质量，降低毒副反应。

Cisplatin combined with capecitabine-induced chemotherapy for local nasopharyngeal carcinoma can improve the quality of life and reduce toxic and side effects.

机构信息

Department of Otorhinolaryngology, Affiliated Hospital of Yan'an University, Yan'an, 716000, Shanxi Province, China.

Department of Cardiovascular Medicine, Affiliated Hospital of Yan'an University, Yan'an, 716000, Shanxi Province, China.

出版信息

World J Surg Oncol. 2021 Sep 17;19(1):280. doi: 10.1186/s12957-021-02393-1.

DOI:10.1186/s12957-021-02393-1
PMID:34535176
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8449458/
Abstract

BACKGROUND

This study was designed to probe into the effect of cisplatin combined with capecitabine on nasopharyngeal carcinoma (NPC).

METHODS

A total of 136 NPC patients treated for the first time in our hospital from January 2016 to March 2017 were collected and divided into two groups: A and B. Among them, 66 in group A were treated with cisplatin intravenous drip, while 70 in group B were treated with capecitabine on the basis of group A. The efficacy, toxic and side effects, and quality of life of the two groups were observed.

RESULTS

The short-term efficacy of group B was better than that of group A (p<0.05). The toxic and side effects of group B were lower than that of group A (p<0.05). The quality of life in group B was higher than that in group A (p<0.05).

CONCLUSIONS

Cisplatin combined with capecitabine-induced chemotherapy for local NPC can improve the quality of life and reduce the toxic and side effects.

摘要

背景

本研究旨在探讨顺铂联合卡培他滨治疗鼻咽癌（NPC）的效果。

方法

收集我院 2016 年 1 月至 2017 年 3 月首次治疗的 136 例 NPC 患者，分为两组：A 组和 B 组。其中，A 组 66 例患者接受顺铂静脉滴注治疗，B 组 70 例患者在 A 组基础上接受卡培他滨治疗。观察两组患者的疗效、毒副反应及生活质量。

结果

B 组近期疗效优于 A 组（p<0.05）。B 组毒副反应发生率低于 A 组（p<0.05）。B 组生活质量优于 A 组（p<0.05）。

结论

顺铂联合卡培他滨诱导化疗治疗局部 NPC 可提高生活质量，降低毒副反应。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8383/8449458/a9d0f11f920b/12957_2021_2393_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8383/8449458/7698a4d8f267/12957_2021_2393_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8383/8449458/13f811dd1583/12957_2021_2393_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8383/8449458/4d8509edc47f/12957_2021_2393_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8383/8449458/a9d0f11f920b/12957_2021_2393_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8383/8449458/7698a4d8f267/12957_2021_2393_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8383/8449458/13f811dd1583/12957_2021_2393_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8383/8449458/4d8509edc47f/12957_2021_2393_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8383/8449458/a9d0f11f920b/12957_2021_2393_Fig4_HTML.jpg

相似文献

1
Cisplatin combined with capecitabine-induced chemotherapy for local nasopharyngeal carcinoma can improve the quality of life and reduce toxic and side effects.顺铂联合卡培他滨诱导化疗治疗局部鼻咽癌可提高生活质量，降低毒副反应。
World J Surg Oncol. 2021 Sep 17;19(1):280. doi: 10.1186/s12957-021-02393-1.
2
NPC-0501 trial on the value of changing chemoradiotherapy sequence, replacing 5-fluorouracil with capecitabine, and altering fractionation for patients with advanced nasopharyngeal carcinoma.NPC-0501 试验评估改变放化疗顺序、用卡培他滨替代 5-氟尿嘧啶以及调整分割剂量方案在晚期鼻咽癌患者中的价值。
Cancer. 2020 Aug 15;126(16):3674-3688. doi: 10.1002/cncr.32972. Epub 2020 Jun 4.
3
Gemcitabine Combined with Cisplatin Has a Better Effect in the Treatment of Recurrent/Metastatic Advanced Nasopharyngeal Carcinoma.吉西他滨联合顺铂治疗复发/转移性晚期鼻咽癌疗效更佳。
Drug Des Devel Ther. 2022 Apr 26;16:1191-1198. doi: 10.2147/DDDT.S353898. eCollection 2022.
4
Induction chemotherapy with lobaplatin and fluorouracil versus cisplatin and fluorouracil followed by chemoradiotherapy in patients with stage III-IVB nasopharyngeal carcinoma: an open-label, non-inferiority, randomised, controlled, phase 3 trial.洛铂联合氟尿嘧啶与顺铂联合氟尿嘧啶诱导化疗后同期放化疗治疗局部晚期鼻咽癌的随机、开放、非劣效、对照、Ⅲ期临床试验
Lancet Oncol. 2021 May;22(5):716-726. doi: 10.1016/S1470-2045(21)00075-9. Epub 2021 Apr 12.
5
[Phase II clinical trial of two different modes of administration of the induction chemotherapy for locally advanced nasopharyngeal carcinoma].[局部晚期鼻咽癌两种不同诱导化疗给药方式的II期临床试验]
Zhonghua Zhong Liu Za Zhi. 2015 Sep;37(9):676-81.
6
Phase II trial of capecitabine plus cisplatin as first-line therapy in patients with metastatic nasopharyngeal cancer.卡培他滨联合顺铂作为转移性鼻咽癌患者一线治疗的 II 期临床试验。
Head Neck. 2012 Sep;34(9):1225-30. doi: 10.1002/hed.21884. Epub 2011 Nov 11.
7
Preliminary results of trial NPC-0501 evaluating the therapeutic gain by changing from concurrent-adjuvant to induction-concurrent chemoradiotherapy, changing from fluorouracil to capecitabine, and changing from conventional to accelerated radiotherapy fractionation in patients with locoregionally advanced nasopharyngeal carcinoma.NPC-0501试验的初步结果，该试验评估了局部晚期鼻咽癌患者从同步辅助放化疗改为诱导-同步放化疗、从氟尿嘧啶改为卡培他滨以及从常规放疗分割改为加速放疗分割后的治疗获益情况。
Cancer. 2015 Apr 15;121(8):1328-38. doi: 10.1002/cncr.29208. Epub 2014 Dec 19.
8
Treatment outcome of docetaxel, capecitabine and cisplatin regimen for patients with refractory and relapsed nasopharyngeal carcinoma who failed previous platinum-based chemotherapy.多西他赛、卡培他滨和顺铂方案治疗既往铂类化疗失败的复发转移性鼻咽癌患者的疗效。
Expert Opin Pharmacother. 2014 Feb;15(2):163-71. doi: 10.1517/14656566.2014.866652. Epub 2013 Dec 3.
9
Phase II study of capecitabine and cisplatin combination as first-line chemotherapy in Chinese patients with metastatic nasopharyngeal carcinoma.卡培他滨和顺铂联合作为中国转移性鼻咽癌患者一线化疗的II期研究。
Cancer Chemother Pharmacol. 2008 Aug;62(3):539-44. doi: 10.1007/s00280-007-0641-2. Epub 2008 Jan 3.
10
[Comparison of efficacy of docetaxel combined cisplatin (TP regimen) and cisplatin combined 5-fluorouracil (PF regimen) on locally advanced nasopharyngeal carcinoma].多西他赛联合顺铂（TP方案）与顺铂联合5-氟尿嘧啶（PF方案）治疗局部晚期鼻咽癌的疗效比较
Ai Zheng. 2007 Aug;26(8):880-4.

引用本文的文献

1
Precision medicine in nasopharyngeal carcinoma: comprehensive review of past, present, and future prospect.鼻咽癌精准医学：过去、现在和未来展望的全面综述。
J Transl Med. 2023 Nov 6;21(1):786. doi: 10.1186/s12967-023-04673-8.
2
Capecitabine-A "Permanent Mission" in Head and Neck Cancers "War Council"?卡培他滨——头颈癌“战争委员会”中的一项“长期任务”？
J Clin Med. 2022 Sep 23;11(19):5582. doi: 10.3390/jcm11195582.

本文引用的文献

1
Correlation between hypoxia-inducible factor-1α C1772T/G1790A polymorphisms and head and neck cancer risk: a meta-analysis.缺氧诱导因子-1α C1772T/G1790A 多态性与头颈部癌症风险的相关性：荟萃分析。
World J Surg Oncol. 2021 Jul 13;19(1):210. doi: 10.1186/s12957-021-02324-0.
2
Current Perspectives on Nasopharyngeal Carcinoma.鼻咽癌的研究现状。
Adv Exp Med Biol. 2019;1164:11-34. doi: 10.1007/978-3-030-22254-3_2.
3
Future of Radiotherapy in Nasopharyngeal Carcinoma.鼻咽癌放射治疗的未来。
Br J Radiol. 2019 Oct;92(1102):20190209. doi: 10.1259/bjr.20190209. Epub 2019 Jul 9.
4
Induction gemcitabine and cisplatin in locoregionally advanced nasopharyngeal carcinoma.诱导吉西他滨和顺铂治疗局部晚期鼻咽癌。
Cancer Commun (Lond). 2019 Jun 25;39(1):39. doi: 10.1186/s40880-019-0385-5.
5
Karnofsky Performance Scale validity and reliability of Turkish palliative cancer patients.卡氏功能状态量表在土耳其癌症终末期患者中的有效性和可靠性。
Turk J Med Sci. 2019 Jun 18;49(3):894-898. doi: 10.3906/sag-1810-44.
6
Bioinformatic identification of candidate biomarkers and related transcription factors in nasopharyngeal carcinoma.鼻咽癌候选生物标志物及相关转录因子的生物信息学鉴定。
World J Surg Oncol. 2019 Apr 1;17(1):60. doi: 10.1186/s12957-019-1605-9.
7
Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study.卡培他滨对比观察用于可切除胆管癌（BILCAP）：一项随机、对照、多中心、3 期研究。
Lancet Oncol. 2019 May;20(5):663-673. doi: 10.1016/S1470-2045(18)30915-X. Epub 2019 Mar 25.
8
Capecitabine for the treatment of pancreatic cancer.卡培他滨治疗胰腺癌。
Expert Opin Pharmacother. 2019 Mar;20(4):399-409. doi: 10.1080/14656566.2018.1560422. Epub 2019 Jan 16.
9
Recent advances in the management of nasopharyngeal carcinoma.鼻咽癌治疗的最新进展
F1000Res. 2018 Nov 21;7. doi: 10.12688/f1000research.15066.1. eCollection 2018.
10
mA-mediated ZNF750 repression facilitates nasopharyngeal carcinoma progression.mA 介导的 ZNF750 抑制促进鼻咽癌的进展。
Cell Death Dis. 2018 Dec 5;9(12):1169. doi: 10.1038/s41419-018-1224-3.